Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death

Vanesa Martín, Guillermo García-Santos, Jezabel Rodriguez-Blanco, Sara Casado-Zapico, Ana Sanchez-Sanchez, Isaac Antolín, Maria Medina, Carmen Rodriguez

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Despite the common expression of death receptors, many types of cancer including gliomas are resistant to the death receptor ligand (TRAIL). Melatonin antitumoral actions have been extensively described, including oncostatic properties on several tumor types and improvement of chemotherapeutic regimens. Here, we found that melatonin effectively increase cell sensitivity to TRAIL-induced cell apoptosis in A172 and U87 human glioma cells. The effect seems to be related to a modulation of PKC activity which in turns decreases Akt activation leading to an increase in death receptor 5 (DR5) levels and a decrease in the antiapoptotic proteins survivin and bcl-2 levels.

Original languageEnglish (US)
Pages (from-to)216-223
Number of pages8
JournalCancer Letters
Issue number2
StatePublished - Jan 28 2010
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


  • Apoptosis
  • Death receptors
  • Glioma
  • Melatonin


Dive into the research topics of 'Melatonin sensitizes human malignant glioma cells against TRAIL-induced cell death'. Together they form a unique fingerprint.

Cite this